Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move: CEO of Lexaria Biosciences Corp (CSE: $LXX.C) (OTC: $LXRP) Talks about Drug Delivery
Platform, Hill Street Beverage Deal
and Human Clinical Trial Results
Delta, Kelowna, BC –August 1, 2018 (Investorideas.com
Newswire) www.Investorideas.com, a global news source covering leading sectors
including marijuana and hemp stocks and its “potcast’ site, www.potcasts.ca release today’s edition of its series, Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at http://www.investorideas.com/news/2018/cannabis/08011Potcasts-CSELXX-CEO.asp
Today’s podcast overview/transcript:
Good morning and welcome to another Investorideas.com potcast – looking
at cannabis news, stocks to watch as well as insights from thought leaders and
experts.
Today I will be talking with Chris Bunka the CEO of Lexaria Biosciences
Corp. trading on the CSE as LXX and the OTC as LXRP.
Lexaria has developed a new disruptive drug delivery platform:
DehydraTECH The Company’s patented technology changes the way Active
Pharmaceutical Ingredients (“APIs”) enter the body orally by masking unwanted
tastes, reducing the time of onset, avoiding first-pass liver metabolism and
increasing bio-absorption by 5-10X.
Interview highlights:
Q:Investorideas.com
Can you explain in simple terms how the company’s delivery technology
DehydraTECH™ works and some of the applications for the technology?
Chris Bunka:
“Our technology can be thought of as a dinner plate, we make a high-tech
dinner plate. What you put on that is up to you. Our plate helps to pile that
drug on and get it into your body more effectively. Our tech is based on some
well-known bio chemistry which it’s the body’s propensity to absorb long chain
fatty acids, similar to sunflower oil or avocado oil. We then “crazy glue” the
long chain fatty acid to the side of the API. When you use our tech, you smell
and taste the oleic acid, which has no taste and smell and masks the smell and
taste of, in this case cannabinoids.”
Q: Investorideas.com
Your company has issued and pending patents in over 40 countries around
the world. That is impressive and somewhat unusual to find in a company
of your size, so can you talk about your Intellectual property and licensing
strategy?
Chris Bunka:
“We have 49 patents pending in 43 countries around the world and 8
patents granted with regards to DehydraTECH. We’re a small company but we punch
above our weight. We are perhaps the only company our size that has completed
all in vitro, in vivo and human clinical studies. We recently released a human
clinical study that was conducted in Europe using our turbo CBD hemp oil
product. In that study we demonstrated that we are able to deliver much more
cannabidiol into a human being and much more quickly. We compared the data to a
previous study done by Mount Sinai Hospital with a cannabidiol provided by GW
Pharmaceuticals (NASDAQ: GWPH) . At the 30-minute mark, using our turbo CBD,
we had over 900% more cannabidiol in blood then they did.”
Recent news:
Significant Bioavailability
Results in Human Clinical Trial using Lexaria’s DehydraTECH (TM) Powered
TurboCBD (TM) Capsules
Q: Investorideas.com
The company is forming four new wholly-owned subsidiaries, one each for
the pharmaceutical, nicotine, hemp, and cannabis industries. Can you talk about
this strategy and what it means for the bigger picture?
Chris Bunka:
“We realize that companies in the
pharmaceutical industry or the nicotine industry even today may not want to
have any association to the cannabis industry, which was one of the reasons we
wanted to build a fence around our different intellectual property assets. We
think this also a good deal for our shareholders as it gives us the opportunity
to take those subsidiaries down slightly different paths with separate
financing which adds versatility to the company, minimizes shareholder dilution
and helps us conduct business with a broader swath of fortune 500 and global
companies.”
Q: Investorideas.com
On your website you say the legal cannabinoid consumer products space is
expected to show Compounded Annual Growth Rate of more than 25% through 2021 in
North America. Do you see that increasing based on federal legalization
here this fall and the push for federal legalization in the US? And where
do you see this industry ten years out ?
Chris Bunka:
“The general answer is yes. I
think the growth rates for cannabinoids edibles is going to be strongly double
digit for the next years to come. I think as the market matures to embrace the
“fat part’ of the demand curve, you’re going to see huge growth in
consumer-friendly methods of ingesting cannabis. I don’t think most people
realize we are in the first or second inning. You’re going to need the
development of edibles legislation, international markets, international
acceptance and societal acceptance. I wouldn’t be surprise to see double digit
growth for a decade or more and in ten years I wouldn’t be surprise to see
cannabis industry bigger then beer or wine.”
Recent news : Lexaria Bioscience and Hill
Street Beverage Company Announce Definitive Agreement for Cannabis-Infused
Beverages
If you would like to be a guest or sponsor this podcast contact
Investorideas.com
Investor ideas reminds
all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy
products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment
Lexaria Bioscience Corp. has developed and
out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and has patents granted in the USA and in Australia for
utilization of its DehydraTECHTM delivery technology. Lexaria's technology
provides increases in intestinal absorption rates; more rapid delivery to the
bloodstream; and important taste-masking benefits, for orally administered
bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules. www.lexariabioscience.com
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on
iTunes, Spotify, Google Play Music,
Stitcher, Spreaker, iHeartradio and
Tunein.
Potcasts is now a certified word
mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires
Big Investing Ideas
Investorideas.com is a recognized news source
publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and
stock news column, Investor
Ideas #Potcasts #Cannabis News and
Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the Stock Guru daily podcast on Support and Resistance Trading.
Disclaimer/Disclosure: Investorideas.com is
a digital publisher of third party sourced news, articles and equity research
as well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure Lexaria
Bioscience Corp. ( CSE: LXX) (OTC: LXRP) is a media sponsor of the podcast
starting July 5 2018 more info
http://www.investorideas.com/About/News/Clientspecifics.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with Sedar.
Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations
of each country.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
Do you trade or invest in Marijuana / Hemp
Stocks? Check out our stock directory of
publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX
Marijuana / Hemp Stocks
Join our Group on Linkedin and talk about - Marijuana / Hemp Stocks - News and Trends in Green Investing
No comments:
Post a Comment